07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

MIV-711: Phase I data

A double-blind, placebo-controlled Phase I trial in 27 healthy volunteers showed that once-daily oral MIV-711 reduced serum levels of the bone resorption biomarker c-terminal telopeptide of type I collage ( CTX-I ) from baseline to...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Clinical News

ViaDerm-Calcitonin: Phase I data

An open-label, crossover Phase I trial in 12 postmenopausal women showed that single doses of 60-300 µg ViaDerm-Calcitonin significantly reduced levels of the bone resorption and cartilage degradation biomarkers C-terminal telopeptide of type I collagen...